Axol buys Newcells’ ophthalmology business to grow drug discovery portfolio
Axol Bioscience has acquired Newcells Biotech’s ophthalmology business to expand its portfolio of drug discovery and safety testing models.
ADVERTISEMENT
About Nick Paul Taylor
This author has not written his bio yet.
But we are proud to say that Nick Paul Taylor contributed 23 entries already.
Entries by Nick Paul Taylor
Amgen wins European approval to challenge argenx and UCB for autoimmune market
The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB.
Zeon invests in Chemify to cut compound synthesis time using AI and robotics
Chemify has struck a deal with Zeon, securing investment from the company’s venture capital wing and signing up to make novel compounds and materials for its new partner.